## **BIOTECHNOLOGY FUND**

	Shares	VALU
ommon stocks <sup>†</sup> - 99.7%		
IOTECHNOLOGY - 70.2%		
Amgen, Inc.	83,681	\$ 17,346,235
Gilead Sciences, Inc.	196,039	15,136,171
Biogen, Inc.*	36,163	12,776,750
Celgene Corp.*	133,628	11,958,37(
Illumina, Inc.*	30,144	11,064,657
Shire plc ADR	61,008	11,058,920
Vertex Pharmaceuticals, Inc.*	55,705	10,736,582
Regeneron Pharmaceuticals, Inc.*	25,070	10,129,283
Alexion Pharmaceuticals, Inc.*	62,504	8,688,68
BioMarin Pharmaceutical, Inc.*	61,838	5,996,43
Incyte Corp.*	82,816	5,720,929
Seattle Genetics, Inc.*	66,628	5,138,35
Exact Sciences Corp.*	58,782	4,639,07
Bio-Rad Laboratories, Inc. — Class A*	14,782	4,626,61
Bluebird Bio, Inc.*	28,786	4,202,75
Alnylam Pharmaceuticals, Inc.*	47,776	4,181,35
Ionis Pharmaceuticals, Inc.*	76,051	3,922,71
Sage Therapeutics, Inc.*	26,342	3,720,80
Ligand Pharmaceuticals, Inc. — Class B*	13,313	3,654,28
United Therapeutics Corp.*	27,750	3,548,67
Exelixis, Inc.*	199,359	3,532,64
Loxo Oncology, Inc.*	20,552	3,510,89
FibroGen, Inc.*	56,138	3,410,38
Intercept Pharmaceuticals, Inc.*	23,374	2,953,53
Blueprint Medicines Corp.*	36,396	2,841,07
Immunomedics, Inc.*	133,796	2,786,97
ACADIA Pharmaceuticals, Inc.*	129,069	2,679,47
Ultragenyx Pharmaceutical, Inc.*	34,900	2,664,26
Myriad Genetics, Inc.*	57,573	2,648,35
AnaptysBio, Inc.*	23,482	2,342,79
Spark Therapeutics, Inc.*	38,124	2,079,66
Amicus Therapeutics, Inc.*	171,580	2,074,40
Medicines Co.* <sup>,1</sup>	68,956	2,062,47
Sangamo Therapeutics, Inc.*	117,634	1,993,89
Puma Biotechnology, Inc.*	41,264	1,891,95
ImmunoGen, Inc.*	190,543	1,804,44
Editas Medicine, Inc.*	55,845	1,776,98
Spectrum Pharmaceuticals, Inc.*	103,310	1,735,60
Esperion Therapeutics, Inc.* <sup>,1</sup>	36,651	1,626,20
Dynavax Technologies Corp.* <sup>,1</sup>	108,210	1,341,80
Radius Health, Inc.*	71,499	1,272,68
otal Biotechnology		207,278,15
HARMACEUTICALS - 25.2%		
AbbVie, Inc.	191,263	18,089,65
Mylan N.V.*	170,680	6,246,88
Neurocrine Biosciences, Inc.*	40,577	4,988,94
Sarepta Therapeutics, Inc.*	30,744	4,965,46
Nektar Therapeutics*	81,404	4,962,38
Jazz Pharmaceuticals plc* <sup>,1</sup>	24,523	4,123,052
PRA Health Sciences, Inc.*	36,285	3,998,244

		Shares	VALUE
		05 202	¢ 2,620,250
Alkermes plc*		85,303	\$ 3,620,259
Agios Pharmaceuticals, Inc.*		40,718	3,140,172
Horizon Pharma plc*		141,753	2,775,524
Array BioPharma, Inc.*		175,759	2,671,537
Ironwood Pharmaceuticals, Inc. — Class A*		139,907	2,582,683
Supernus Pharmaceuticals, Inc.*		47,750	2,404,213
TESARO, Inc.* <sup>1</sup>		54,921	2,142,468
Pacira Pharmaceuticals, Inc.*		40,515	1,991,312
Global Blood Therapeutics, Inc.*		51,181	1,944,878
Portola Pharmaceuticals, Inc.* <sup>,1</sup>		72,593	1,933,152
Clovis Oncology, Inc.*		59,253	1,740,261
Total Pharmaceuticals			74,321,091
HEALTHCARE-SERVICES - 2.5%			
Charles River Laboratories International, Inc.*		28,958	3,896,009
Syneos Health, Inc.*		68,120	3,511,586
Total Healthcare-Services			7,407,595
HEALTHCARE-PRODUCTS - 1.8%			
Bio-Techne Corp.		20,311	4,145,678
MiMedx Group, Inc.* <sup>,1</sup>		200,620	1,239,832
Total Healthcare-Products			5,385,510
Total Common Stocks			204 202 254
(Cost \$151,401,506)			294,392,354
RIGHTS <sup>†††</sup> - 0.0%			
Clinical Data, Inc.* <sup>,2</sup>		24,000	
Total Rights			
(Cost \$—)			
		_	
		FACE	
		Amount	
REPURCHASE AGREEMENTS <sup>††,3</sup> - 0.4%			
JP Morgan Chase & Co.			
issued 09/28/18 at 2.24%	*	502 (32	502 (32
due 10/01/18	\$	583,413	583,413
Barclays Capital			
issued 09/28/18 at 2.23%			
due 10/01/18		288,260	288,260
Bank of America Merrill Lynch			
issued 09/28/18 at 2.25%			
due 10/01/18		192,173	192,173
Total Repurchase Agreements			
(Cost \$1,063,846)			1,063,846

## **BIOTECHNOLOGY FUND**

	SHARES	VALUE
SECURITIES LENDING COLLATERAL <sup>†,4</sup> - 2.6% Money Market Fund		
First American Government Obligations Fund — Class Z, 1.94% <sup>5</sup>	7,564,640	\$ 7,564,640
Total Securities Lending Collateral (Cost \$7,564,640)		7,564,640
Total Investments - 102.7% (Cost \$160,029,992)		\$ 303,020,840
Other Assets & Liabilities, net - (2.7)%		(7,831,157)
Total Net Assets - 100.0%		\$ 295,189,683

- \* Non-income producing security.
- <sup>†</sup> Value determined based on Level 1 inputs.
- <sup>††</sup> Value determined based on Level 2 inputs.
- <sup>†††</sup> Value determined based on Level 3 inputs.
- <sup>1</sup> All or a portion of this security is on loan at September 30, 2018.
- <sup>2</sup> Security was fair valued by the valuation committee at September 30, 2018. The total market value of fair valued securities amounts to \$0, (cost \$0) or less than 0.1% of total net assets.
- <sup>3</sup> Repurchase Agreements.
- <sup>4</sup> Securities lending collateral.
- <sup>5</sup> Rate indicated is the 7-day yield as of September 30, 2018. ADR — American Depositary Receipt
- plc Public Limited Company